Projektbeschreibung
Neue Biopharmazeutika gegen Erkrankungen des Zentralnervensystems
Europaweit sind Millionen von Menschen von Erkrankungen des Zentralnervensystems (ZNS) betroffen, z. B. Multipler Sklerose oder der Alzheimer- und Parkinson-Krankheit. Gängige Arzneimittel haben jedoch eine geringe Bioverfügbarkeit und werden in das ZNS direkt, vor allem aber invasiv über den Liquorraum (intrathekal), die Hirnkammer (intrazerebroventrikulär) oder das Gewebe (intraparenchymal) injiziert. Um diese Hürde zu umgehen, schult das EU-finanzierte Projekt Bio2Brain Nachwuchsforschende in innovativen Technologien, um Biopharmazeutika auf sicherem Weg über die Nase zu verabreichen. Damit soll das Projekt die Wirkstoffverfügbarkeit für das ZNS verbessern, u. a. von Biopharmazeutika wie monoklonalen Antikörpern, um so eine der größten Herausforderungen bei der Behandlung von ZNS-Erkrankungen auszuräumen.
Ziel
Bio2Brain aims to create a trans-European network of industrially oriented specialists fully trained and experienced, a significant driving force in innovating novel technologies to deliver biopharmaceuticals safely and via the nasal route of administration to the central nervous system (CNS). Diseases of the CNS and the spinal cord affect around 165 million Europeans with disorders such as Multiple Sclerosis, Alzheimer’s disease and Parkinson’s disease. CNS disorders are often connected with high morbidity, significant side effects, suffering of the patients and their families, as well as an enormous burden on the welfare systems. Therefore, in terms of social sustainability, Bio2Brain contributes to increased benefit for both, the society as whole and particularly for those individuals at a disadvantage through these disorders. A highly critical challenge of CNS diseases is the low central availability drugs in general and in particular of biopharmaceuticals like monoclonal antibodies (mAbs). Hence, approved medicinal products with a low CNS bioavailability are currently delivered via intrathecal, intracerebroventricular or intraparenchymal injections. In this way, they are delivered directly to the CNS. Unfortunately, such delivery systems are invasive, require a surgery with high risks, have a low patient compliance and are poorly controllable. Therefore, there is a critical need for a more safe and effective new approach, that means a paradigm shift, for drug delivery technologies in the treatment of CNS diseases. The Bio2Brain network will create a research environment for the interdisciplinary and intersectorial training of 13 ESRs supported by 11 academic teams (beneficiaries and partner universities), 6 key industrial stakeholders and an academic non-profit organization. As an important benefit, the close and frequent exposure of the ESRs to the private sector and to key technologies will significantly enhance their employability.
Wissenschaftliches Gebiet
Schlüsselbegriffe
Programm/Programme
Thema/Themen
Aufforderung zur Vorschlagseinreichung
Andere Projekte für diesen Aufruf anzeigenFinanzierungsplan
MSCA-ITN - Marie Skłodowska-Curie Innovative Training Networks (ITN)Koordinator
80686 Munchen
Deutschland